Benassi SK, Alves JGSM, Guidoreni CG, Massant CG, Queiroz CM, Garrido-Sanabria E, Loduca RDS, Susemihl MA, Paiva WS, de Andrade AF, Teixeira MJ, Andrade JQ, Garzon E, Foresti ML, Mello LE (2021) Two decades of research towards a potential first anti-epileptic drug. Seizure 90:99-109. doi: 10.1016/j.seizure.2021.02.031
Objective: To evaluate the efficacy of biperiden in preventing the development of epilepsy in patients that suffered traumatic brain injury (TBI), in a double blind, randomized, placebo-controlled trial.
Summary: Biperiden, a selective M1 anti-muscarinic drug, presented disease-modifying actions in the pilocarpine model of epilepsy. The presented evidence from epilepsy models gives further support to the authors’ strategy to concentrate efforts on anti-cholinergic compounds, rather than on classical anti-seizure drugs.
Usage: An i.c.v. injection into the right lateral ventricle of 5μL of 192-IgG-SAP (IT-01) at a 0.85 μg/μL concentration.
Related Products: 192-IgG-SAP (Cat. #IT-01)